CLINICAL_TRIALS ClinicalTrials.gov record update

A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT02486718
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-10-01T00:03:37.769577+00:00
Published At: 2025-03-30T00:00:00+00:00
Record Updated At: 2026-09-30
Results Posted At: 2025-03-30
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Non-Small Cell Lung Cancer"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-09-30"
protocolSection.identificationModule.nctId: "NCT02486718"
protocolSection.identificationModule.officialTitle: "A Phase III, Open-Label, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Best Supportive Care Following Adjuvant Cisplatin-Based Chemotherapy in Patients With Completely Resected Stage IB-IIIA Non-Small Cell Lung Cancer"
protocolSection.statusModule.overallStatus: "COMPLETED"
protocolSection.designModule.phases: ["PHASE3"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: "2025-03-30"

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.